Out of stock
Amoxiclav 125 mg + 31.25 mg in suspension is intended for the treatment of bacterial infections caused by microorganisms sensitive to the drug:
acute bacterial sinusitis;
acute otitis media;
exacerbation of chronic bronchitis confirmed;
infections of the skin, soft tissues, animal bites;
infections of bones, joints (osteomyelitis).
The presence of clavulanic acid in the suspension of Amoxiclav 125 mg + 31.25 mg protects amoxicillin from the destruction of β-lactamases, expands the spectrum of its antibacterial action with the inclusion of microorganisms that are usually resistant to other penicillins and cephalosporins.